It has been about a month since the last earnings report for Vertex Pharmaceuticals (VRTX) . Shares have added about 15.8% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Vertex due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Q1 Earnings Beat, Trikafta Drives SalesV ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium also includes the Zacks Style Score ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this drugmaker have returned +9.7%, compared to the Zacks S&P 500 composite's +3.2% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Vertex falls in, has gained 2.4%. The key question now is: What could be the stock's future direction?Altho ...

Vertex Pharmaceuticals Incorporated (VRTX) has been benefiting from strong revenue growth, regulatory approvals and commercial launches in the past year.Vertex enjoys a dominant position in the cystic fibrosis (CF) market. Vertex’s CF sales continue to grow, driven by its triple therapy, Trikafta (marketed as Kaftrio in Europe). In the United States, Trikafta sales are being fueled by label expansions to younger age groups (two to five years old). In the ex-U.S. markets, the drug continues to witness strong ...

Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way, just may have authored a new playbook for life sciences R&D.Founded in 1989, Vertex’s rollercoaster story is most iconically characterized by the rise and fall of Incivek, a hepatitis C drug that reached $1 billion in sales faster than any before it, only to be withdrawn from the market just three years after ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks ...

The biotech's shares dropped following its latest quarterly update, but that shouldn't matter to long-term investors.There are several textbook arguments against monopolies. According to one of them, companies that control a market can lower the quality of their products with impunity.However, Vertex Pharmaceuticals (VRTX 0.91%), a drugmaker with a monopoly in the cystic fibrosis (CF) market, hasn't done that -- quite the contrary. Since it launched its first CF product some 12 years ago, the biotech hasn't ...

For the quarter ended March 2024, Vertex Pharmaceuticals (VRTX) reported revenue of $2.69 billion, up 13.3% over the same period last year. EPS came in at $4.76, compared to $3.05 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2.56 billion, representing a surprise of +5.15%. The company delivered an EPS surprise of +16.10%, with the consensus EPS estimate being $4.10.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 ____________________________________________ Vertex Pharma ...

Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2024 adjusted earnings per share of $4.76, which beat the Zacks Consensus Estimate of $4.10. Earnings increased 56% year over year, driven by higher product revenues, lower costs and a lower tax rate in the quarter.The company reported total revenues of $2.69 billion, comprising cystic fibrosis (CF) product revenues. The figure beat the Zacks Consensus Estimate of $2.56 billion. Total revenues rose 13% year over year, primarily driven by high ...